Search

Shannon L Kesl

from Los Angeles, CA
Age ~39
Get Report
Related to:
Cari A Brown, 66Peggy L Kesl, 69Maureen A Kesl, 95Jennifer X Fry, 67Robert L Kesl, 67Jeanette F Kesl, 61John R Fry, 82Jennifer Kesl
Connected to:
Andrew R Kesl, 38Stefan Keslacy, 47Allen R Keslar, 52Clifford E Keslar, 73Letha M Keslar, 46Melissa Keslar, 33Becky G Kesler, 59Brenda S Kesler, 60Charli E Kesler, 32Christina Kesler, 78

Shannon Kesl Phones & Addresses

  • Los Angeles, CA
  • 6130 Coke Ave, Long Beach, CA 90805
  • Killeen, TX
  • Temple Terrace, FL
  • Plant City, FL
  • Springfield, OH

Work

Company: University of south florida Jan 2016 to Jun 2016 Position: Research specialist

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of South Florida Specialities: Philosophy

Skills

Wound Healing • Metabolism • Energy Metabolism • Medical Research • Research • Laboratory • Molecular Pharmacology • Physiology • Cell Culture • Small Animal Models • Small Animal Surgery • Immunohistochemistry • Microscopy • Small Animal Diet Design • Small Animal Blood Draws • Small Animal Gavage • Laser Doppler • Cellular Assays

Industries

Research

Resumes

Resumes

Shannon Kesl Photo 1

Research Scientist

View page
Location:
6130 Coke Ave, Long Beach, CA 90805
Industry:
Research
Work:
University of South Florida Jan 2016 - Jun 2016
Research Specialist
Epigenix Foundation Jan 2016 - Jun 2016
Research Scientist
University of South Florida Aug 2010 - Dec 2015
Graduate Research Assistant and Doctoral Candidate
Moffitt Cancer Center Jun 2009 - Jun 2010
Research Intern
Dr Stacey Edwards Do May 2009 - Jan 2010
Medical Receptionist
Education:
University of South Florida
Doctorates, Doctor of Philosophy, Philosophy
Skills:
Wound Healing
Metabolism
Energy Metabolism
Medical Research
Research
Laboratory
Molecular Pharmacology
Physiology
Cell Culture
Small Animal Models
Small Animal Surgery
Immunohistochemistry
Microscopy
Small Animal Diet Design
Small Animal Blood Draws
Small Animal Gavage
Laser Doppler
Cellular Assays

Publications

Us Patents

Metabolic Therapy For Wound Healing

View page
US Patent:
20210093602, Apr 1, 2021
Filed:
Dec 15, 2020
Appl. No.:
17/122479
Inventors:
- Tampa FL, US
Shannon Kesl - Tampa FL, US
International Classification:
A61K 31/231
A61K 31/19
A61K 31/198
A61K 31/047
A61K 31/22
A61K 36/889
A61P 17/02
Abstract:
Ketone supplementation, such as through use of precursors of beta-hydroxybutyrate (BHB) and acetoacetate (AcAc), increased blood levels of ketone bodies, increases blood flow and wound closure in ischemic young and aged fisher rats significantly earlier compared to standard diet in aged rats. In vitro experiments with ketone bodies demonstrate decreased mitochondrial and cytosolic ROS in young and aged primary human dermal fibroblasts (PHDF). Ketone bodies increased migration in young and aged PHDFs.

Compositions And Methods For Producing Elevated And Sustained Ketosis

View page
US Patent:
20200268701, Aug 27, 2020
Filed:
May 11, 2020
Appl. No.:
16/871686
Inventors:
- Tampa FL, US
Patrick Arnold - Champaign IL, US
Shannon Kesl - Long Beach CA, US
International Classification:
A61K 31/23
A61K 31/047
A61K 31/22
A61K 31/19
A61K 31/20
A23L 2/52
Abstract:
Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Compositions And Methods For Producing Elevated And Sustained Ketosis

View page
US Patent:
20170266148, Sep 21, 2017
Filed:
Jun 1, 2017
Appl. No.:
15/610668
Inventors:
Dominic Paul D'Agostino - Tampa FL, US
Patrick Arnold - Champaign IL, US
Shannon Kesl - Long Beach CA, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 31/23
A61K 31/20
A23L 2/52
A61K 31/22
A61K 31/047
A61K 31/19
Abstract:
Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Methods Of Sustaining Dietary Ketosis And Its Effects On Lipid Profile

View page
US Patent:
20170172969, Jun 22, 2017
Filed:
Mar 7, 2017
Appl. No.:
15/451891
Inventors:
Dominic Paul D'Agostino - Tampa FL, US
Shannon Kesl - Killeen TX, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 31/225
Abstract:
The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (HO) (n≧8). Days 1-28, rats received a daily 5 g/kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 μl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until βHB returned to baseline. At day 1 and 28, 10 μL of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.

Methods Of Sustaining Dietary Ketosis And Its Effects On Lipid Profile

View page
US Patent:
20160317487, Nov 3, 2016
Filed:
Jul 11, 2016
Appl. No.:
15/206673
Inventors:
Dominic Paul D'Agostino - Tampa FL, US
Shannon Kesl - Killeen TX, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 31/225
Abstract:
The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (HO) (n≧8). Days 1-28, rats received a daily 5 g/kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 μl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until βHB returned to baseline. At day 1 and 28, 10 μL of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.

Compositions And Methods For Producing Elevated And Sustained Ketosis

View page
US Patent:
20160067207, Mar 10, 2016
Filed:
Sep 21, 2015
Appl. No.:
14/860092
Inventors:
Dominic Paul D'Agostino - Tampa FL, US
Patrick Arnold - Champaign IL, US
Shannon Kesl - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
A61K 31/23
A61K 31/19
Abstract:
Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Compositions And Methods For Producing Elevated And Sustained Ketosis

View page
US Patent:
20140350105, Nov 27, 2014
Filed:
Aug 8, 2014
Appl. No.:
14/455385
Inventors:
Dominic Paul D'Agostino - Tampa FL, US
Patrick Arnold - Champaign IL, US
Shannon Kesl - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 31/23
A23L 2/52
A61K 31/19
US Classification:
514547
Abstract:
Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
Control profile
Shannon L Kesl from Los Angeles, CA, age ~39 Get Report